Cargando…

Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin

BACKGROUND AND AIMS: Prescription Drug Monitoring Programs (PDMPs) were designed to curb opioid misuse and diversion by tracking scheduled medications prescribed by medical providers and dispensed by pharmacies. The effects of PDMPs on opioid prescription, misuse and overdose rates have been mixed d...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickson-Gomez, Julia, Christenson, Erika, Weeks, Margaret, Galletly, Carol, Wogen, Jennifer, Spector, Antoinette, McDonald, Madelyn, Ohlrich, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013627/
https://www.ncbi.nlm.nih.gov/pubmed/33854323
http://dx.doi.org/10.1177/1178221821992349
_version_ 1783673501998120960
author Dickson-Gomez, Julia
Christenson, Erika
Weeks, Margaret
Galletly, Carol
Wogen, Jennifer
Spector, Antoinette
McDonald, Madelyn
Ohlrich, Jessica
author_facet Dickson-Gomez, Julia
Christenson, Erika
Weeks, Margaret
Galletly, Carol
Wogen, Jennifer
Spector, Antoinette
McDonald, Madelyn
Ohlrich, Jessica
author_sort Dickson-Gomez, Julia
collection PubMed
description BACKGROUND AND AIMS: Prescription Drug Monitoring Programs (PDMPs) were designed to curb opioid misuse and diversion by tracking scheduled medications prescribed by medical providers and dispensed by pharmacies. The effects of PDMPs on opioid prescription, misuse and overdose rates have been mixed due in part to variability in states’ PDMPs and difficulties measuring this complexity, and a lack of attention to implementation and enforcement of PDMP components. The current study uses qualitative interviews with key informants from 3 states with different PDMPs, Connecticut, Kentucky and Wisconsin to explore differences in the characteristics of the PDMPs in each state; how they are implemented, monitored and enforced; and unintended negative consequences of these programs. METHODS: We conducted in-depth interviews with key informants from each state representing the following sectors: PDMP and pain clinic regulation agencies, Medicaid programs, state licensing boards, pharmacies, emergency medicine departments, pain management clinics, first responders, drug courts, drug treatment programs, medication assisted treatment (MAT) providers, and harm reduction organizations. Interview guides explored participants’ experiences with and opinions of PDMPs according to their roles. Data analysis was conducted using a collaborative, constant comparison method. RESULTS: While all 3 states had mandated registration and reporting requirements, the states differed in the implementation and enforcement of these and the extent to which provider prescribing was monitored. These, in turn, influenced how medical providers perceived the PDMP and changed how providers prescribed opioids. Unintended consequences of state PDMPs included under-prescribing for pain and “dumping” patients who were long term users of opioids or who had developed opioid use disorders and may explain the increase in illicit heroin or opioid use. CONCLUSION: State PDMPs with similar mandates may differ greatly in implementation and enforcement. These differences are important to consider when determining the effects of PDMPs on opioid misuse and overdose.
format Online
Article
Text
id pubmed-8013627
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80136272021-04-13 Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin Dickson-Gomez, Julia Christenson, Erika Weeks, Margaret Galletly, Carol Wogen, Jennifer Spector, Antoinette McDonald, Madelyn Ohlrich, Jessica Subst Abuse Original Research BACKGROUND AND AIMS: Prescription Drug Monitoring Programs (PDMPs) were designed to curb opioid misuse and diversion by tracking scheduled medications prescribed by medical providers and dispensed by pharmacies. The effects of PDMPs on opioid prescription, misuse and overdose rates have been mixed due in part to variability in states’ PDMPs and difficulties measuring this complexity, and a lack of attention to implementation and enforcement of PDMP components. The current study uses qualitative interviews with key informants from 3 states with different PDMPs, Connecticut, Kentucky and Wisconsin to explore differences in the characteristics of the PDMPs in each state; how they are implemented, monitored and enforced; and unintended negative consequences of these programs. METHODS: We conducted in-depth interviews with key informants from each state representing the following sectors: PDMP and pain clinic regulation agencies, Medicaid programs, state licensing boards, pharmacies, emergency medicine departments, pain management clinics, first responders, drug courts, drug treatment programs, medication assisted treatment (MAT) providers, and harm reduction organizations. Interview guides explored participants’ experiences with and opinions of PDMPs according to their roles. Data analysis was conducted using a collaborative, constant comparison method. RESULTS: While all 3 states had mandated registration and reporting requirements, the states differed in the implementation and enforcement of these and the extent to which provider prescribing was monitored. These, in turn, influenced how medical providers perceived the PDMP and changed how providers prescribed opioids. Unintended consequences of state PDMPs included under-prescribing for pain and “dumping” patients who were long term users of opioids or who had developed opioid use disorders and may explain the increase in illicit heroin or opioid use. CONCLUSION: State PDMPs with similar mandates may differ greatly in implementation and enforcement. These differences are important to consider when determining the effects of PDMPs on opioid misuse and overdose. SAGE Publications 2021-03-25 /pmc/articles/PMC8013627/ /pubmed/33854323 http://dx.doi.org/10.1177/1178221821992349 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Dickson-Gomez, Julia
Christenson, Erika
Weeks, Margaret
Galletly, Carol
Wogen, Jennifer
Spector, Antoinette
McDonald, Madelyn
Ohlrich, Jessica
Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin
title Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin
title_full Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin
title_fullStr Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin
title_full_unstemmed Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin
title_short Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin
title_sort effects of implementation and enforcement differences in prescription drug monitoring programs in 3 states: connecticut, kentucky, and wisconsin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013627/
https://www.ncbi.nlm.nih.gov/pubmed/33854323
http://dx.doi.org/10.1177/1178221821992349
work_keys_str_mv AT dicksongomezjulia effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin
AT christensonerika effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin
AT weeksmargaret effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin
AT galletlycarol effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin
AT wogenjennifer effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin
AT spectorantoinette effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin
AT mcdonaldmadelyn effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin
AT ohlrichjessica effectsofimplementationandenforcementdifferencesinprescriptiondrugmonitoringprogramsin3statesconnecticutkentuckyandwisconsin